| DOV |
Report |
Q2 2026 adjusted EPS |
BEAT |
pred ~$2.78 vs. cons $2.72 |
MEDIUM |
| DOV |
Report |
Q2 2026 revenue |
BEAT |
pred ~$2.25B vs. cons $2.21B |
MEDIUM |
| DOV |
Report |
Q2 2026 adjusted segment EBITDA margin |
IN-LINE |
pred ~25.4% vs. cons 25.2% |
LOW |
| DOV |
Guide |
Adjusted EPS guidance |
BETTER |
guide ~$10.75 midpoint vs. cons $10.63 (FY2026) |
MEDIUM |
| DOV |
Guide |
Organic revenue growth guidance |
BETTER |
guide ~5.0% midpoint vs. cons 4.8% (FY2026) |
MEDIUM |
| DOV |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.6% |
— |
MEDIUM |
| DOV |
Return |
5-day cumulative residual |
+4.8% (FOLLOW-THROUGH) |
A ~$10.75 FY2026 guide and ~$5.06 H1 adjusted EPS imply ~$5.69 of H2 EPS versus the pre-report consensus requirement of ~$5.63, supporting modest positive out-period revisions after the initial beat. |
MEDIUM |